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Vascular inflammation and endothelial dysfunction are key elements in the progression of cardiovascular disease 
(CVD). In most conditions that are considered cardiovascular 
risk factors (eg, hypercholesterolemia and hypertension), the 
vascular system or, more specifically, vascular endothelium 
incites an inflammatory response that leads to the develop-
ment of adherent and dysfunctional endothelial cell, which in 
turn contributes to vascular damage and risk for CVD.1
In women, the processes involved in vascular damage are 
thought to be slowed by the presence of estrogen.2 Nevertheless, 
available data on the effects of estrogens on inflammatory pro-
cess are fairly contradictory, with both anti-inflammatory3,4 
and proinflammatory5 effects reported. This is further compli-
cated by discrepant data from prospective randomized clinical 
studies aimed to determine the effects of estrogen replacement 
therapy on circulating markers of inflammation in postmeno-
pausal women. These studies described that biomarkers such 
as adhesion molecules and interleukins (ILs) can be increased, 
decreased, or unchanged after estrogen treatment.4,6,7
Type of estrogen and cell/tissue studied, acute or chronic 
stimuli, degree of tissue injury, and differences in end points 
used to define the inflammatory response are some of the 
factors that may explain these discrepancies. In addition, there 
is a recent consensus that cardiovascular protective effects 
of estrogen may be influenced by the timing of initiation of 
estrogen therapy. A recent theory, called timing hypothesis, 
has postulated that the effects of estrogen to prevent CVD may 
occur only when treatment is initiated before the detrimen-
tal effects of aging on CVD are established in the vascula-
ture.8 Aging, per se, is known to have a positive relationship 
with the levels of inflammation biomarkers and increased risk 
of CVD.9 Nonetheless, it is currently unknown whether the 
effects of estrogen on vascular function and, more specifically, 
vascular inflammation are modified by aging in women. In 
this regard, the present study aims to evaluate the relationship 
of aging with vascular inflammation biomarkers and how time 
since menopause affects the modulation of inflammatory bio-
markers by estrogen and raloxifene in arteries of postmeno-
pausal women.
Methods
The protocol was approved by the Ethics Committee of Clinical 
Research (Comite Etico de Investigacion Clinica Protocol 2007/3916) 
from Hospital Clinic de Barcelona and conducted in compliance with 
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Aging, Estrogen, and Vascular Inflammation
Objective—Our study aims to determine the role of time of menopause on vascular inflammation biomarkers and how it 
affects their modulation by estrogen and raloxifene in postmenopausal women.
Methods and Results—Uterine arteries from 68 postmenopausal women were divided into 3 segments and cultured for 24 
hours in tissue culture media containing 17β-estradiol (100 nmol/L), raloxifene (100 nmol/L), or vehicle. Assessment 
of arterial concentration of 13 inflammatory biomarkers was performed by multiplex immunobead-based assay. Aging 
per se has a positive correlation with the generation of several proinflammatory markers. Although short-term estradiol 
exposure correlates with lower expression of tumor necrosis factor-α, vascular endothelial growth factor, and interleukin-
1β in all age groups, for most biomarkers aging was associated with a switch from a beneficial anti-inflammatory action 
by estrogen, at earlier stages of menopause, to a proinflammatory profile after 5 years past its onset. Raloxifene has no 
significant effect on the expression of all proinflammatory markers. Western blot analysis of estrogen receptor expression 
(estrogen receptor-α and estrogen receptor-β) showed that estrogen receptor-β increases with aging, and this increase has 
a positive correlation with the generation of several proinflammatory markers.
Conclusion—Aging alters estrogen-mediated effects on the modulation of inflammatory biomarkers in women. How 
aging affects estrogen responses on vascular inflammation is not clear, but our data show a positive association between 
increased estrogen receptor-β expression with aging and proinflammatory effects by estrogen. (Arterioscler Thromb 
Vasc Biol. 2012;32:2035-2042.)
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the principles of the Helsinki Declaration. Uterine arteries were 
obtained from 68 women who underwent hysterectomy because of 
uterine prolapse or myoma from September 2007 to June 2009. All 
patients provided written informed consent to participate in the study. 
Women who have never been on hormone replacement therapy or 
selective estrogen receptor modulators (raloxifene and tamoxifen) 
were matched for body mass index, blood pressure, lipids, and lipopro-
teins. Exclusion criterion includes use of chronic anti-inflammatory 
therapy, statins, angiotensin-converting enzyme inhibitors, and angio-
tensin receptor type 1 antagonist. At the moment of hysterectomy, 
arteries were cleaned, divided into 3 segments, and cultured for 24 
hours in tissue culture media containing 17β-estradiol (100 nmol/L), 
raloxifene (100 nmol/L), or vehicle for further analysis of inflam-
mation biomarkers and estrogen receptor (ER) expression. Detailed 
methods related to tissue culture and treatments, multiplex assay, and 
Western blot are shown in the online-only Data Supplement.
Data Analysis
Time since menopause was defined by the age at which a woman last 
had any menstrual bleeding and expressed as years passed since last 
menstruation until the day of hysterectomy. Inflammation biomarker 
concentration in each sample was expressed as mean concentration 
from triplicate measurements normalized by the amount of protein 
in each sample. The degree of linear relationship between time since 
menopause and biomarker concentration found in each group (ie, 
estrogen-treated, raloxifene-treated, and untreated groups), as well 
as the correlation between ER-α or ER-β expression (in untreated 
arteries) and biomarker concentration after treatments (estrogen or 
raloxifene), was expressed as regular linear regression compared 
with the use of Pearson correlation coefficient, expressed as Pearson 
r value, ranging from −1 (inverse correlation) to +1 (positive correla-
tion). The proportion of variation response shared by the 2 variables 
in the model is expressed as r2. Significant correlation was accepted 
at P<0.05. ANCOVA was used to compare the slopes of correlations 
from untreated arteries with the slopes obtained by different treat-
ments (17β-estradiol or raloxifene). The magnitude of estrogen and 
raloxifene effects on inflammation biomarker concentration in asso-
ciation with time since menopause was performed by combination of 
samples in age groups as follows: menopausal women up to 5 years 
before hysterectomy (<5); women between 5 and 10 years past the 
onset of menopause (5–10); and women >10 years past menopause 
(>10). Association between time since menopause in grouped sam-
ples and estrogen or raloxifene treatments was assessed using 2-way 
ANOVA, followed by Bonferroni post-test to compare replicate 
means. Statistical analysis and Pearson coefficient calculation were 
carried out using SPSS Statistics v18.0 software (IBM, Armonk, NY).
Results
Clinical characteristics of women who provide uterine arter-
ies are presented in the Table. Despite all care in obtaining 
samples from patients without history of CVD, a few women 
in this study have presented some degree of cardiovascular 
risk factors, including hypertension and hypercholesterol-
emia, which were equally distributed among aging groups. No 
racial/ethnic-based evaluation was performed.
Aging per se has a positive correlation with vascular inflam-
mation. Eight of 13 markers displayed a sizeable positive 
relationship between time since menopause and inflamma-
tory biomarkers (Table I in the online-only Data Supplement). 
ANCOVA revealed that short-term estradiol exposure signifi-
cantly affects aging-associated correlation observed in most 
biomarkers (Figure 1). Estrogen treatment changed the degree 
of linear correlation of inflammatory biomarkers in association 
with time since menopause, although these effects were not 
uniform for all markers studied (Figure 1). Although estrogen 
treatment was associated with a reduction in the  concentration 
of IL-1β, vascular endothelial growth factor, and tumor necro-
sis factor (TNF-α) at any stage of menopause, an increased 
correlation was observed for monocyte chemotactic protein-1 
and the adhesion molecules soluble intercellular adhesion 
molecule-1 and soluble vascular cell adhesion molecule-1. 
In addition, treatment with estrogen created a correlation that 
had not previously existed between the production of IL-6 
and IL-8 and time of menopause (Figure 1). Raloxifene had 
no significant effects on the relationship of time since meno-
pause with all proinflammatory markers studied (Table I in the 
online-only Data Supplement). When arteries were grouped 
by time after menopause, we observed a bidirectional effect 
of estrogen. Although estrogen treatment was associated with 
lower expression of the markers TNF-α, vascular endothe-
lial growth factor, and IL-1β in all age groups (Figure 2), for 
most of the inflammation biomarkers, time of menopause was 
associated with a switch from a beneficial anti-inflammatory 
action by estrogen, at earlier stages of menopause, to a pro-
inflammatory profile after 5 years past its onset (Figure 3). 
Western blot analysis of ER-α expression in nontreated arter-
ies reveals the presence of 2 splicing variants of this receptor 
in the arterial wall, the 66-kDa (ER66) and the 46-kDa (ER46) 
isoforms (Figure 4A). Time since menopause does not modify 
the expression of ER66, whereas a slight, although not sig-
nificant, increase in the ER46 isoform was observed in the 
>10-year group (Figure 4A). Analysis of ER46/ER66 ratio 
was found to have no correlation with time since menopause 
(Figure 4C). On the other hand, although ANOVA showed no 
statistical significance among aging groups (ER46/ER66 ratio: 
<5 group, 0.57±0.03; 5–10 group, 0.63±0.05; >10 group, 
0.70±0.07), a significant aging-associated linear trend increase 
in ER46/ER66 was observed (ANOVA post-test for linear 
Table. Baseline Demographic and Clinical Characteristics
Characteristics
Age, mean (SD) 58 (13)
Time since menopause (y), n (%)
 <5 30 (44)
 5–10 17 (25)
 >10 21 (31)
Reason for hysterectomy, n (%)
 Myoma 39 (57)
 Uterine prolapse 29 (43)
BMI, mean (SD) 28 (3.5)
Total cholesterol (mg/dL), mean (SD) 212 (22)
Triglycerides (mg/dL), mean (SD) 91 (19)
History of CVD, n (%)
 Hypertension 14 (21)
 Stroke 0 (0)
 Angina 0 (0)
Smoking, n (%)
 Never 54 (80)
 Past 9 (13)
 Current 5 (7)
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trend: P=0.0075). As for ER-β, we observed a linear trend of 
increase in ER-β expression with aging (ANOVA post-test for 
linear trend: P=0.013), which becomes significantly higher 
past 10 years of menopause onset (Figure 4B). A similar pat-
tern of responses on ER-α and ER-β expressions was found in 
arterial segments that were treated with 17β-estradiol or ralox-
ifene (data not shown), suggesting that there is no modulation 
of ER expression by these agonists in our experimental condi-
tions (24 hours of treatment at 100 nmol/L). By correlating the 
expression of ERs with arterial biomarkers of inflammation, 
no association was found between these markers and ER-α 
expression (Figure I in the online-only Data Supplement). 
However, a significant positive relationship was observed 
between ER-β expression and the proinflammatory effects of 
estrogen (Figure 5). Interestingly, we also found a lower, but 
positive, correlation between the expression of ER-β and the 
concentration of TNF-α and IL-1β, 2 biomarkers that were 
found to be downregulated by estrogen (Figure 5).
Discussion
Our data are a first step toward the understanding the effects 
of aging, or rather time since menopause, in the modulation 
of vascular inflammation by estrogen. Based on the principle 
of the timing hypothesis, the anti- or proinflammatory poten-
tial of 2 estrogenic molecules (17β-estradiol and raloxifene) 
was carefully determined by treating arterial segments from 
women at different stages of menopause.
Together with the known risk factors, findings from 
epidemiological and basic studies have tightly linked inflam-
matory process with vascular aging.10,11 Plasma levels of 
several cytokines, especially IL-6 and TNF-α, have been 
described to be increased with age even in apparently healthy 
individuals and in the absence of acute infection.12,13 We found 
that aging has a positive correlation with several markers of 
vascular inflammation in arteries from menopausal women. 
Of the 13 markers analyzed, we observed a significant degree 
Figure 1. Simple correlation analysis 
between time since menopause (x axis) 
and concentration of biomarkers of 
inflammation (y axis) in uterine  arteries 
untreated (NT) and treated with 100 
nmol/L 17β-estradiol (E2). Shown are the 
inflammatory biomarkers that expressed 
significant changes in the degree 
of  correlation after E2 treatment, as 
 determined by ANCOVA. TNF-α indicates 
tumor necrosis factor-α; VEGF, vascular 
endothelial growth factor; IL, interleukin; 
MCP1, Monocyte chemotactic protein-1; 
s-ICAM, soluble intercellular adhesion 
molecule-1; s-VCAM, soluble vascular 
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of correlation in 8 of them, including the adhesion molecules 
E-selectin, soluble intercellular adhesion molecule-1 and 
soluble vascular cell adhesion molecule-1, the cytokines 
IL-1α and TNF-α, and the chemokine monocyte chemotactic 
protein-1. Our data agree with previous studies establishing 
that aging process is associated with a development of a more 
adhesive endothelium. Increased leukocyte adhesion and 
enhanced expression of adhesion molecules and chemokines 
have been observed in older individuals compared with 
young adult,11 as well as in senescent endothelial cells.14 On 
the other hand, even though our results corroborate previous 
studies showing an aging-associated increase in the cytokines 
TNF-α and IL-1β, our major surprise was related to the lack 
of correlation with IL-6, which has been widely described 
in the literature to be associated with vascular aging process 
and increased cardiovascular risk. However, the fact that IL-6 
concentration was determined in plasma by the majority of 
studies demonstrates the complexity on the modulation of 
inflammation in different tissues. Although several inflam-
matory markers may arise from atheroma plaque, reflecting 
the extent of inflammation within the vascular lesion, they 
might also come from nonvascular sources, reflecting inflam-
matory states, such as chronic infections. As yet, the field still 
needs to better establish the role and the modulation of the 
distinct inflammatory markers in the vessel wall during the 
progression of CVD and aging.
Because women are less likely to progress to CVD, a sex-
associated difference in inflammatory responses has been 
proposed. In fact, recent autopsy studies have described that 
inflammatory atherosclerosis and associated acute coronary 
heart disease develop earlier in life in men than in women 
and are associated with death at an earlier age, although both 
men and women present the same overall plaque burden.15 
Also in animal models for atherosclerosis, male sex contrib-
utes to the progression of lipid deposition, remodeling, and 
aortic lesions.16–18 Despite evidences, the mechanisms of such 
gap are largely unknown, and few studies have addressed this 
issue by determining the anti- and proinflammatory potential 
of estrogen in the vasculature. Nonetheless, the available data 
are rather inconclusive and fairly contradictory. Estrogen has 
been described to suppress vascular inflammation by down-
regulation of proinflammatory molecules, including cytokines 
and adhesion molecules.6,7,19–22 Inflammatory response has also 
been shown to vary significantly according to the estrous cycle 
in rodents.23 On the other hand, several clinical studies have 
described estrogen as a proinflammatory modulator in auto-
immune diseases.5 Meta-analysis of clinical evidence on the 
modulating effects of estrogens reveals a striking discrepancy 
with both anti- and proinflammatory effects being described.4
There is much controversy over the design and interpretation 
of the clinical studies to determine the effects of estrogen in the 
cardiovascular system. Recent studies have suggested that the 
cardiovascular protective effects of estrogen may be influenced 
by the type of estrogen and the timing of initiation of estrogen 
therapy. Furthermore, the most used hormone replacement 
therapy not only contains estrogenic compounds but also 
progestins and, importantly, androgens that may interfere with 
the beneficial effects of estradiol.24 We have recently shown 
that equine estrogens display a lower transcriptional activity 
and lower ability to modulate endothelial function than the 
naturally occurring estrogen, 17β-estradiol.25 Consistently, 
increased inflammatory effects by estrogens were mostly found 
in women treated with conjugated equine estrogens, whereas 
others have found reduced or unaffected levels of the same 
biomarkers when women were treated with 17β-estradiol.4
In addition to estrogens, a large number of women are being 
exposed to selective estrogen receptor modulators to prevent 
breast cancer recurrence and osteoporosis. According to sev-
eral experimental and observational studies, the selective estro-
gen receptor modulator raloxifene has beneficial effects on 
the vascular system. Similar to estrogen, raloxifene treatment 
has shown favorable effects on lipid profile and endothelial 
Figure 2. Effects of treatments with 17β-estradiol (E2) or raloxi-
fene (ralox) on the expression of inflammatory biomarkers in uter-
ine arteries of women grouped by age, according to time past 
the onset of menopause: <5 years (<5); between 5 and 10 years 
(5–10); and >10 years of menopause (>10). Shown are the bio-
markers in which E2 displayed an anti-inflammatory action in all 
age groups. Data are plotted as mean±SEM. *P<0.05, **P<0.01, 
and *** P<0.001. TNF-α indicates tumor necrosis factor-α; VEGF, 
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function.26,27 With regard to its potential as a modulator of 
vascular inflammation, the little information available reveals 
similar inconsistency as estrogen.28 In these studies, we found 
that short-term treatment with raloxifene does not affect the 
degree of correlation between time past menopause and bio-
markers of inflammation. On the other hand, we observed that 
17β-estradiol displays an overall inflammatory effect, because 
the treatment of arteries with this hormone increases the degree 
of aging-associated relationship for most biomarkers studied.
However, although our results initially suggest an inflam-
matory effect by estrogens, a careful look at the data reveals 
a likely bidirectional effect of estrogen in some inflammatory 
biomarker that is dependent on age range. In this regard, a 
second analysis was performed by grouping samples accord-
ing to time since menopause: up to 5 years of menopause (<5); 
between 5 and 10 years of menopause (5–10); and >10 years 
past the onset of menopause (>10). With this analysis, we 
observed that acute treatment with estrogen induces an anti-
inflammatory effect only in arteries from women at early stages 
of menopause (up to 5 years). In arteries of older women or 
women who have more years in menopause, estrogen begins 
to display a timing-dependent proinflammatory effect, sug-
gesting that aging plays a negative role on estrogen-mediated 
effects on vascular inflammation. In fact, detailed examination 
of the data from the Women’s Health Initiative indicates that 
early initiation of estrogen replacement produces more favor-
able results than the late average time of initiation used in the 
Women’s Health Initiative studies overall.29–31 In support with 
this hypothesis are few studies showing that aging in female 
rodents is associated with significant reduction in estrogen-
mediated cardiovascular effects.32–34 In addition, studies have 
described that timing of onset for estrogen replacement alters 
the immunologic environment and the progression of vascular 
inflammation and atherosclerosis formation. Ovariectomized 
Figure 3. Effects of treatments with 17β-estradiol (E2) or raloxifene (ralox) on the expression of inflammatory biomarkers soluble 
 intercellular adhesion molecule-1 (s-ICAM), soluble vascular  cell adhesion molecule-1 (s-VCAM), interleukin (IL)-6, IL-8, and monocyte 
chemotactic protein-1 (MCP1) in uterine arteries of women grouped by age, according to time past the onset of menopause: <5 years 
(<5); between 5 and 10 years (5–10); and >10 years of menopause (>10). Shown are the biomarkers in which E2 displayed a bidirectional 




 http://ahajournals.org by on A
ugust 7, 2020
2040  Arterioscler Thromb Vasc Biol  August 2012
women receiving estrogen immediately after ovariectomy had 
significantly smaller atherosclerotic lesions than those under-
going delayed or no estrogen exposure.35
On the other hand, acute treatment with 17β-estradiol was 
effective in decreasing the arterial levels of IL-1β and TNF-α 
in all age groups, despite keeping the positive correlation of 
those markers with aging. Both are major inflammatory cyto-
kines crucially involved in early stages of vascular inflam-
mation. Through endothelial stimulation, IL-1β and TNF-α 
increase in synthesis and release of adhesion molecules 
ICAM and VCAM and set off the inflammatory cascade.36 
Corroborating our data are numerous experimental studies 
describing that estradiol downregulates TNF-α and IL-1β in 
different cell types and suggesting an anti-inflammatory and 
vasculoprotective action by estrogens.3
However, although a decrease in levels or action of 
specific cytokines has been attributed to lower risk of CVD, 
the functional specificity of each biomarker to the process 
of chronic inflammation and progression of vascular disease 
remains uncertain. It is important to note that the mechanisms 
of actions of these inflammatory markers are highly pleiotropic 
and often share common pathways and, therefore, could act on 
other molecules synergistically even when they are at lower 
concentrations. In fact, there are reports that genetic deletion 
and pharmacological neutralization of TNF-α fail to reduce 
atherosclerosis in mice.37,38 Unfortunately, our study fails to 
establish how this unbalanced modulation of inflammatory 
biomarkers (ie, decrease of TNF-α and IL-1β in the presence 
of augmented levels of other biomarkers, would account for 
the overall process of vascular inflammation), and even more 
important is how the acute effects of estrogen observed could 
be translated into protection or vascular damage in the long 
run. The major contribution of this study was to demonstrate 
the aging-associated dichotomy that exists on the effects 
of estrogen on inflammatory biomarkers, which draws our 
attention to the need of further prospective studies designed to 
better establish the effects of estrogen in the process of vascular 
inflammation and risk of CVD in postmenopausal women.
The mechanisms whereby aging and long-term estrogen 
withdrawn affect estrogenic responses are largely unknown, 
but our data suggest a relationship between changes on 
balance of ERs (ER-α isoforms and ER-β) with increased 
proinflammatory effect by estrogen. The differences in 
signaling through ER-α and ER-β are increasingly becoming 
apparent, and, in fact, previous experimental studies have 
established that increased expression of ER-β over ER-α is 
associated with higher oxidative stress and atherosclerotic 
plaque formation.39,40 Furthermore, emerging evidences have 
shown the physiological and pathophysiological relevance 
of 2 variants of ER-α to estrogen signaling—the full-length 
ER-α with 66-kDa (ER66) and the ER-α isoform lacking the 
N-terminal portion (ER46).41,42 Both isoforms are expressed in 
the endothelial cells and are able to increase NO production.41 
In this regard, a slight increase in ER46 expression, as observed, 
would represent a benefit to the vascular wall. However, 
studies have described that ER46 dimerizes with ER66 and 
Figure 4. Expression of estrogen receptor 
(ER)-α (A) and ER-β (B) in untreated uterine 
arteries of women grouped by age, accord-
ing to time past the onset of menopause: <5 
years (<5); between 5 and 10 years (5–10); 
and >10 years of menopause (>10). Values 
for ER-α isoforms, 46 kDa (ER46) and 66 kDa 
(ER66), and ER-β were normalized by the 
corresponding optical density for GAPDH, 
used as the internal control. Data are plot-
ted as mean±SEM. Significant correlation 
is accepted at P<0.05. Simple correlation 
analysis between time since menopause  
(x axis) and expression of ER-α splicing vari-
ants ratio (46kDa/66kDa) (C) and ER-β (D)  
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serves as a competitive inhibitor of ER66 for DNA binding,43 
and therefore an increase in ER46 may interfere with ER66 
transcriptional activity and modify estrogenic responses in a 
given cell. Such dual effect of ER46 could bias the efficiency 
of estrogen to modulate vascular inflammation, although we 
cannot determine in which direction this effect would occur, 
as both a positive and negative regulation might take place in 
the vessel wall. Although we interpret the results on changes 
of ER profile as responsible for reversing the beneficial effects 
of estrogen, we were unable to provide evidence on whether 
the relationship between aging and ER expression is worse 
or modified at long term, or yet, whether it can be altered by 
estrogen treatment. Nonetheless, the question still arises as to 
how the crosstalk between ER-α isoforms (ER46 and ER66) 
and ER-β modulates the effects of estrogen in the vascular wall. 
Unfortunately, sample size in these studies prevented us from 
further investigation of these precise mechanisms. Entirely new 
protocols and new samples are needed to address this issue and 
to improve our knowledge on the mechanisms for aging and 
hormonal regulation of vascular function. Despite that, our data 
demonstrate that estrogen has complex biological effects under 
distinct pathophysiological conditions and may influence the 
risk of cardiovascular events and other outcomes. How aging 
affects estrogen responses and to what extent these changes 
can modify the risk for CVD remain unknown, but our data 
strongly suggest that the time to start hormone replacement 
therapy should be taken into account when deciding the best 
therapy to treat postmenopausal women.
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